Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Galactooligosaccharide (GOS) is a prebiotic carbohydrate composed of galactose units, typically produced through the enzymatic treatment of lactose. It functions by selectively stimulating the growth and activity of health-promoting gut bacteria, particularly *Bifidobacterium* and *Lactobacillus* species. By modulating the gut microbiota, GOS helps maintain intestinal barrier integrity, reduces colonic permeability, and may lower systemic inflammation. It has been investigated in clinical trials for its potential to manage ulcerative colitis, improve metabolic markers in obese individuals, and provide neuroprotective effects in conditions like amyotrophic lateral sclerosis (ALS) by influencing B-vitamin absorption and homocysteine levels. GOS is frequently utilized in synbiotic formulations to support the establishment of probiotic strains in the human gastrointestinal tract.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on galactooligosaccharide.